INTRODUCTION
The liver faces a major challenge in NEFA (non-esterified fatty acid) influx. To prevent the threat of potential hepatic lipotoxicity, the liver converts the NEFAs into the more physicochemically inert TAGs (triacylglycerols) or oxidizes them to ketones. TAG constitutes the most concentrated form of energy in vertebrates. However, its extremely hydrophobic nature hampers its transport in the ionic milieu of the plasma. Hepatocytes resolve this problem through the formation and secretion of the TAG-rich lipoprotein, VLDL [very-LDL (low-density lipoprotein)]. As a result, most of the TAG circulating in the plasma during the post-absorptive state is associated with VLDL. VLDL is composed of a core of neutral lipids, which is surrounded by phospholipids, cholesterol and specific apolipoproteins. Of several apolipoproteins, apoB100 (apolipoprotein B 100) is the essential component of VLDL and its metabolites IDL (intermediate-density lipoprotein) and LDL. The assembly of VLDL starts in the ER (endoplasmic reticulum) with MTP (microsomal TAG transfer protein)-mediated partial lipidation of apoB100 and then the bulk of the neutral TAG is added to the poorly lipidated apoB100-containing particle [1] [2] [3] [4] [5] . The intracellular site of VLDL maturation remains unclear despite many efforts to identify it. A number of studies report that VLDL maturation occurs in the ER [2, [6] [7] [8] [9] [10] [11] , whereas other studies suggest that the Golgi is the site where the formation of mature VLDL takes place [12-14a] .
Transport of newly synthesized proteins and lipids from the ER to the Golgi is a multi-step process and is mediated by specialized vesicles. These vesicles bud from donor membranes, the ER, and fuse with acceptor membranes, the Golgi, to deliver their distinct cargoes. Newly synthesized proteins exit the ER in classical COPII (coatamer protein II)-coated vesicles [referred to in the present study as PTVs (protein transport vesicles)] [15, 16] . The COPII coat contains five different cytosolic proteins, Sar1, Sec23-Sec24 and Sec13-Sec31 [15, 16] . The orderly recruitment of these proteins to the ER membranes leads to cargo selection and vesicle generation [15] [16] [17] . Sar1 in its GTP form is recruited first on to the ER membrane followed by the sequential binding of Sec23-Sec24 and Sec13-Sec31 [17, 18] . The size of these vesicles ranges from 55 nm to 70 nm [17] , limiting their ability to accommodate larger cargo such as chylomicrons (average diameter of ∼ 250 nm) [19] . A unique large vesicle, the PCTV (pre-chylomicron transport vesicle), mediates ER-to-Golgi transport of chylomicrons in enterocytes [20, 21] . The generation of PCTVs does not require COPII proteins; however, they do contain COPII proteins [21] , which are important for Golgi targeting. Studies in McA-RH7777 cells have shown that the generation of VLDL-carrying vesicles from the ER is COPII-dependent [22] . Although these vesicles require COPII proteins and were of ∼ 55-70 nm in size, they were different from PTVs [22] . Furthermore, it was suggested that VLDL exits in the ER as a poorly lipidated LDL-sized particle [22] and thus smaller vesicles were able to accommodate immature VLDL.
Despite many similarities between primary hepatocytes and various hepatocyte-derived cell lines such as the human hepatoma cell HepG2 and the rat hepatoma cell McA-RH7777, the process Abbreviations used: apoB, apolipoprotein B; COPII, coatamer protein II; DTT, dithiothreitol; ECL, enhanced chemiluminescence; EM, electron microscopy; EndoH, endoglycosidase H; ER, endoplasmic reticulum; ERK, extracellular-signal-regulated kinase; HRP, horseradish peroxidase; LDL, lowdensity lipoprotein; MEK, mitogen-activated protein kinase/ERK kinase; MTP, microsomal triacylglycerol transfer protein; NEFA, non-esterified fatty acid; OA, oleic acid; PCTV, pre-chylomicron transport vesicle; PNS, post-nuclear supernatant; PTV, protein transport vesicle; SNARE, soluble N-ethylmaleimidesensitive fusion protein-attachment protein receptor; TAG, triacylglycerol; TCA, trichloroacetic acid; VAMP7, vesicle-associated membrane protein 7; VLDL, very-LDL; VTV, VLDL transport vesicle.
1 email ssiddiqi@utmem.edu of VLDL biogenesis in these systems is variable. For example, HepG2 cells secrete smaller VLDL particles as compared with primary hepatocytes [23] . A recent study suggests that the MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellularsignal-regulated kinase) kinase]/ERK pathway plays an important role and is responsible for the poor lipidation of apoB100 that results in secretion of small-sized VLDL particles [24] . Both HepG2 and McA-RH7777 cells express high levels of ERK1/2 whereas primary hepatocytes isolated from hamster do not contain recognizable ERK1/2 [24] . Furthermore, Hansson et al. [25] reported that McA-RH7777 cells metabolize a lipid load as well as glucose differently than do primary hepatocytes. These findings suggest that the formation and maturation of VLDL particles differ in primary hepatocytes when compared with hepatoma cell lines. Since PCTVs exit the ER containing pre-chylomicrons approximating the size of mature chylomicrons, the possibility was considered that a similar situation might exist in primary hepatocytes. In the present study efforts are described to characterize a vesicle that is shown to transport VLDL from the ER to the Golgi in this cell system. To study the ER exit step, a cell-free system was developed, which allowed isolation of an hepatic ER-derived VLDLcontaining vesicle. In the present study the isolation and characterization of a COPII-dependent, functional vesicular fraction of light buoyant density that excludes albumin, a major hepatic secretory protein, and vectorially transfers VLDL from the ER to the Golgi of rat primary hepatocytes is described. It is further shown that VTV (VLDL transport vesicle) fuses with liver cisGolgi and delivers VLDL to the Golgi lumen. 
EXPERIMENTAL

Antibodies and recombinant protein
Polyclonal antibodies against mammalian Sar1 have been described previously [21] . Rabbit polyclonal antibodies against rat VAMP7 (vesicle-associated membrane protein 7; amino acids 105-123) have been characterized previously [26] . Rabbit polyclonal antibodies raised against rat apoB [26a] were a gift of Dr Larry Swift (Department of Pathology, Vanderbilt University, Nashville, TN, U.S.A.). Rabbit polyclonal anti-rat albumin antibodies were purchased from Bethyl Laboratories. Goat anticalnexin and anti-transferrin antibodies, goat anti-rabbit IgG, goat anti-mouse IgG and goat anti-rabbit IgG conjugated with HRP (horseradish peroxidase) were purchased from Santa Cruz Biotechnology. Goat anti-rabbit IgG conjugated with agarose beads was purchased from Sigma. Rabbit polyclonal anti-rSec22b antibodies were a gift from Dr Jesse Hay (Division of Biological [27, 28] . Briefly, small pieces (3 mm × 5 mm × 0.5 mm) of rat liver (4-5 g) were cut, washed with icecold 0.25 M sucrose in 10 mM Hepes (pH 7.2), incubated with 100 μCi of [ 14 C]OA (0.004 mM) plus 0.1 mM (or 0.4 mM as indicated in Figure legends) of OA complexed to bovine albumin for 30 min at 37
• C and homogenized in buffer A [10 mM Hepes (pH 7.2), 0.25 M sucrose, 0.5 mM EGTA and protease inhibitors] using a Parr bomb. The ER fraction was isolated using a sucrose step gradient and the ER fraction was re-isolated in a second sucrose step gradient [21, 26] .
When Figure 1 ).
Preparation of cytosol, cis-and trans-Golgi
Cytosol was prepared from freshly harvested rat liver essentially employing the same methodology as described by Kumar and Mansbach [29] . Small pieces (3 mm × 5 mm × 0.5 mm) of rat liver (6 g) were washed with ice-cold 0.25 M sucrose in 10 mM Hepes (pH 7.2), blotted and homogenized in ice-cold buffer B [25 mM Hepes (pH 7.2), 125 mM KCl, 2.5 mM MgCl 2 , 0.5 mM DTT (dithiothreitol), 0.5 mM EGTA and protease inhibitors] using four strokes of a motor-driven serrated glass/Teflon homogenizer. The liver homogenate was further homogenized using a Parr bomb at 6210 kPa for 40 min, centrifuged at 600 g for 10 min and the resultant PNS (post-nuclear supernatant) was collected. The PNS was centrifuged at 100 000 g for 90 min at 4
• C and the supernatant was collected as cytosol. The cytosol was dialysed against ice-cold buffer C [25 mM Hepes (pH 7.2), 125 mM KCl, 2.5 mM MgCl 2 , 0.5 mM DTT and protease inhibitors] for 6 h at 4
• C, concentrated using a Centricon Filter (Amicon) with a 10 kDa cut-off to 20 mg of protein/ml.
For the isolation of non-radiolabelled cis-and trans-Golgi, washed small liver pieces (3 mm × 5 mm × 0.5 mm; 4-5 g) were homogenized in ice-cold buffer A and the PNS was prepared. The cis-and trans-Golgi fractions were isolated using a sucrose step gradient and the cis-and trans-Golgi fractions were re-isolated in a second sucrose step gradient [21, 26, 30] . The purity of the cisand trans-Golgi was established by immunoblotting for marker proteins (Figure 1 ).
In vitro ER budding assay
VTV generation from rat liver ER (500 μg of protein) containing either [ 14 Hepatic ER, cis-and trans-Golgi membranes were prepared. Samples (each containing 30 μg of protein) of ER, cis-Golgi or hepatic cell lysate (TM) were separated by SDS/PAGE (12 % gel), transblotted on to a nitrocellulose membrane and probed with specific antibodies to TGN38, GOS28, calnexin and Rab11. For details, see the Experimental section. diluted to 0.1 M sucrose, overlaid on top of a continuous sucrose gradient [21, 30] , centrifuged in an SW41 rotor (Beckman) at 25 900 rev./min for 2 h at 4
• C, and the gradient was resolved with a gradient eluter [21, 29] . Fractions of 0.5 ml were collected, [
14 C]TAG was extracted from the samples by differential organic solvent extraction [29] , and the d.p.m. were determined in a scintillation counter. When double-labelled ER was used, [ 14 C]TAG was extracted from the samples by differential organic solvent extraction and [ 3 H]protein precipitated with TCA (trichloroacetic acid) and the d.p.m. was determined in a scintillation counter using a double isotope technique [21] .
In vitro VTV-Golgi fusion assay
VTV (150 μg of protein) containing [
14 C]TAG and [ 3 H]protein were incubated with cis-Golgi (300 μg of protein), an ATPgenerating system, rat liver cytosol (500 μg of protein), in a buffer containing 1 mM GTP, 2.5 mM Ca 2+ , 5 mM Mg 2+ , 2 mM DTT, 30 mM KCl and 30 mM Hepes (pH 7.2) for 30 min at 37
• C. The reaction was stopped by adding ice-cold buffer, adjusted to 1.22 M sucrose and placed at the bottom of a sucrose step gradient [29, 31] . The gradient was centrifuged in a SW41 rotor for 3 h at 25 900 rev./min at 4
• C and the cis-Golgi fraction which floated at the 0.86/1.15 M density interface was collected by aspiration. The [
14 C]TAG was extracted using the same procedure as described by Kumar and Mansbach [29] and the d.p.m. were determined. [ 3 H]apoB100 was immunoprecipitated as described below and the d.p.m. were measured.
Immunoprecipitation of apoB100
After the fusion assay, cis-Golgi membranes were isolated, solubilized in ice-cold PBS containing 1 % (v/v) Triton X-100 and incubated with 20 μl of rabbit anti-apoB antibodies for 4 h at 4
• C. Anti-rabbit IgGs bound to agarose beads were added subsequently. After overnight incubation at 4
• C, immune complexes bound to beads were isolated and washed 10 times with ice-cold PBS to remove unbound proteins completely.
EndoH (endoglycosidase H) treatment of apoB100
Immunoprecipitated [
3 H]apoB100 was incubated with EndoH (500 units) for 20 h at 37
• C, separated by SDS/PAGE (5-15 %), and were then autoradiographed.
EM (electron microscopy)
Negative staining was used to visualize the morphology of VTVs. First, glow-discharged nickel-grids coated with carbon and formvar [32] were overturned on top of a drop of VTVs, incubated for 2-3 min and rinsed with PBS and water. Samples were stained with 0.5 % aqueous uranyl acetate for 1 min, blotted on filter paper, air-dried and examined under a JEOL 1200 EX electron microscope at 12 000× magnification.
Measurement of TAG and protein radioactivity
TAG-associated radioactivity was measured by radioscintigraphy [29] . Protein radioactivity was quantified after precipitation with TCA. For doubly labelled ER-budding assays, the dual-isotope mode was used on the scintillation analyser (TriCarb, Model 1500, Packard Instrument).
Gel electrophoresis, Western blotting and autoradiography
Protein samples were prepared in Laemmli's buffer, separated by SDS/PAGE and transblotted on to nitrocellulose membranes (BioRad). After blocking the membrane with 5 % (w/v) non-fat dried skimmed milk in PBS, membranes were incubated with specific primary, and then appropriate secondary, antibodies conjugated with HRP. Proteins were detected using ECL ® reagents and exposing the developed blots to Kodak Biomax film [21] .
For autoradiography, proteins were separated by SDS/PAGE and gels were rinsed three times with distilled water and stained with SimplyBlue TM SafeStain (Invitrogen). After destaining with distilled water, gels were dried and autoradiographed using Kodak Biomax film at − 70
• C.
Proteinase K treatment
Vesicles were treated with proteinase K at a final concentration of 0.1 mg/ml for 30 min at 4
• C in the absence or presence of 2 % (v/v) Triton X-100. After incubation, proteinase K was neutralized with an excess of PMSF.
Immunodepletion of Sar1
Immunodepletion of Sar1 from rat liver cytosol was performed in a similar manner as described previously [21] . Briefly, cytosol (2 mg of protein) was incubated overnight at 4
• C with rabbit antiSar1 antibodies bound to agarose beads. Beads were removed by centrifugation (1000 g for 2 min) and cytosol was dialysed against ice-cold buffer C and concentrated using centricons YM-10.
Statistical analysis
Comparisons between means were carried out using a statistical package supplied by GraphPad Software (Instat, GraphPad Software) using a two-tailed t test.
RESULTS
Purity of subcellular fractions
First, the purity of the subcellular fractions isolated from primary hepatocytes was established. The cis-Golgi preparation contained GOS28 (Figure 1) but not calnexin or Rab11 (Figure 1 ), ruling out ER or endosomal/lysosomal contamination of the Golgi. TGN38, a trans-Golgi marker, was mostly present in trans-Golgi fractions, whereas cis-Golgi had very little (Figure 1 ). The ER fraction contained calnexin, an ER-resident protein, but did not have recognizable GOS28, a cis-Golgi protein, and Rab11, an endosomal/lysosomal protein ( Figure 1 ). These results indicate that the ER and Golgi fractions were of adequate purity to be used in the in vitro assays.
Establishment of in vitro VTV budding
To study the transport of VLDL from the ER in primary rat hepatocytes, an in vitro ER budding assay was established. Hepatic ER, containing [ 14 C]TAG as a marker for VLDL, was incubated at 37
• C for 30 min in the presence of cytosol, GTP and an ATPregenerating system. Post-incubation, the reaction mix was resolved on a continuous sucrose-density gradient (0. incubated with an ATP-regenerating system at 37
• C in the absence of cytosol ( Figure 2B , bar 2), or with cytosol boiled for 5 min ( Figure 2B, bar 3 ), cytosol treated with proteinase K ( Figure 2B , bar 4), or when the complete reaction mix was incubated at 4
• C ( Figure 2B, bar 5) . Budding of VTV from hepatic ER requires ATP, since no VTV formation occurred when the ATP-regenerating system was replaced with 5 mM glucose and 25 units/ml hexokinase [32] (Figure 2B, bar 6 ) or when ATP was replaced with 20 units/ml apyrase ( Figure 2B, bar 7) .
To examine the distribution of VTVs and PTVs in the continuous sucrose gradient, hepatic radiolabelled ER containing Under these conditions, I determined that 14-15 % of the nascent TAG was shifted from the ER to the putative VTV fraction during a 30 min incubation compared with 12-14 % of newly synthesized proteins, consistent with prior observations in the intestine [21] .
To support the hypothesis that two populations of vesicles were present, I examined the distribution of apoB (both apoB100 and apoB48), known to be present in rat VLDL [33] : Sar1, a marker for ER-derived vesicles [15, 18] , calnexin, an ER-resident protein [34] , and albumin and transferrin, markers for secretoryprotein-containing vesicles [35] , across the gradient as identified by immunoblots ( Figure 2D ). As expected, apoB100 and apoB48 were found in light sucrose-density fractions ( Figure 2D ), whereas albumin and transferrin were present mainly in the mid-portion of the gradient, the expected location of PTVs ( Figure 2D ), consistent with observations in enterocytes [21] . Although Sar1 was distributed in most of the fractions, it was concentrated in fractions 5 and 6 and fractions 9 and 10 ( Figure 2D) . Calnexin was present only in budding reaction mix (TM in Figure 2D ). These results suggest that VLDL exits the hepatic ER in a distinct vesicle that does not contain albumin or transferrin, consistent with previous reports [14a,22] . In addition, these results further support the hypothesis that VTVs have a relatively lighter density than PTVs.
To observe the proposed vesicles morphologically, I concentrated fractions 4-7 ( Figure 2C ) and examined the concentrated fractions by EM. Figure 3(A) shows a myriad of vesicles ranging in diameter from 100 to 120 nm. To visualize putative PTVs, fractions 9-11 ( Figure 2C ) were concentrated and a sample was observed by negative-staining EM. A field of pure vesicles ranging in size from 55-70 nm is shown ( Figure 3B ). These results indicate that primary hepatic ER-derived VTVs ( Figure 3A ) are relatively larger in size than PTVs ( Figure 3B ) budded from the same ER.
The size of VLDL varies and depends on the amount of TAG available for its assembly. To determine the effect of different concentrations of TAG on VTV distribution in sucrose density gradients, I incubated primary hepatocytes with different amounts of OA (0.004 mM, 0.1 mM and 0. 4 VTVs (A) and PTVs (B) were generated from hepatic ER as in Figure 2 (C). The VTVs (fractions 4-7) and the PTVs (fractions 9-11) were examined by EM using the negative-staining technique (for details, see the Experimental section).
particle. Next, I wished to determine the effect of OA treatment of these hepatocytes on the apoB content of VTVs, budded from their respective ERs. As shown in Figure 4 (B), there was an increase in apoB100 and apoB48 in VTVs budded from the ER of hepatocytes incubated with 0.4 mM OA (+OA) as compared with when OA was absent (−OA). However, this increase was relatively higher for apoB48 ( Figure 4B ). These results suggest that when cells were incubated with OA, the amount of both apoB48 and apoB100 was increased in VLDL, consistent with prior observations [36] . The results presented in Figures 4(A) and 4(B) raise another possibility that the treatment of hepatocytes with 0.4 mM OA increases the number of budded VTVs because these vesicular fractions contain more TAG and apoB (100 and 48) as well. However, this interpretation seems not feasible, because OA treatment of the cells resulted in VTVs of lighter buoyant density ( Figure 4A ), suggesting that VTVs generated under these conditions contain more lipidated VLDL particles.
One criterion for vesicle formation is that they are sealed. To address this issue, I incubated VTVs, budded from ER isolated from hepatocytes incubated with 0.4 mM OA (+OA) or without OA (−OA), with proteinase K at a final concentration of 0.1 mg/ml for 30 min at 4
• C in the absence or presence of Triton X-100. After incubation, proteinase K was neutralized with an excess of PMSF. Proteinase K treatment of VTVs (+OA and −OA) did not reduce the apoB100 signal as compared with untreated VTV (Figure 5A ). By contrast, when VTVs were treated with proteinase K in the presence of 2 % (v/v) Triton X-100 to disrupt vesicle membranes, the apoB100 signal was totally abolished ( Figure 5A ). These results indicate that VTVs have acquired an intact membrane during budding from hepatic ER prepared from hepatocytes treated either with (+OA) or without (−OA) OA. These results provide strong evidence that VTVs are sealed and that apoB within the VTV does not have a fragment exposed to the cytosol.
VTVs bud from ER membranes, concentrate apoB100 and ER-to-Golgi transport proteins, and are different from PTVs
A characteristic of transport vesicles is that cargo proteins and other proteins [such as specific SNARE (soluble N-ethylmaleimide-sensitive fusion protein-attachment protein receptor) proteins, proteins required for the formation of these vesicles, etc.] are concentrated in the vesicle, whereas non-specific proteins (proteins that are not sorted to be packaged into a specific vesicle) from the donor membranes are excluded. To determine whether VTVs met this criterion, VTV proteins were immunoblotted for various proteins such as apoB100, a marker for VTV cargo, the VLDL and Sar1, a component of COPII and rSec22b, a v-SNARE of ER-derived vesicles. I also immunoblotted for the ER-resident protein, calnexin, which would be expected to be excluded from VTV. I compared immunoblots for these proteins in VTV with its parent membrane, ER, using equal amounts of protein. As expected for an ER-to-Golgi transport vesicle, Sar1 and rSec22b were both concentrated in VTV compared with ER ( Figure 5B ). ApoB100, a cargo protein of VTV, was also concentrated ( Figure 5B ). By contrast, the ER-localized protein, calnexin, was excluded from VTV but gave a robust signal in ER ( Figure 5B ). These results support the conclusion that VTV are ER-to-Golgi transport vesicles and not the result of membrane fragmentation or other artefactual events.
Next, I wished to find out whether VTV contains albumin or not. As was expected, albumin was present in hepatic ER ( Figure 5B ), whereas no albumin signal was found in VTV ( Figure 5B ). These results support the hypothesis that VTVs differ from vesicles, which transport newly synthesized proteins from the ER to the Golgi.
VTV budding from the ER requires Sar1
Since VTV concentrates Sar1, a GTPase required for PTV budding from ER membranes, I wished to determine whether it is required for VTV formation as well. As a first approach to the functionality of Sar1 in VTV generation, Sar1 protein was immunodepleted from the cytosol prior to budding ( Figure 6A ). I further washed ER membranes with 2 M urea to remove the Sar1 known to be present in native ER [21] (Figure 6A ). Mock-depleted cytosol and mock-washed ER membranes were used as controls. The removal of Sar1 greatly reduced the ability of ER membranes to generate VTV by comparison with the mock-depleted system ( Figure 6B ). As a second approach to the importance of Sar1 in VTV formation, I utilized H89, a kinase inhibitor known to block Sar1 recruitment to ER membranes [37] . When H89 was added to the VTV budding reaction, VTV generation was greatly reduced as compared with native conditions ( Figure 6B ). One interpretation of these results is that Sar1 is required for VTV formation, supporting the work of Gusarova et al. [22] .
VTV fuses with cis-Golgi and delivers nascent VLDL to the Golgi lumen
Another major criterion for ER-to-Golgi transport vesicles is that they are able to fuse with their target Golgi membranes and deliver their cargo to the cis-Golgi lumen. To determine the fusion competency of VTV with hepatic Golgi, I developed an in vitro fusion assay. VTVs containing [
14 C]TAG and [ 3 H]apoB were incubated with unlabelled acceptor hepatic cis-Golgi in the presence of hepatic cytosol and an ATP-regenerating system at 37
• C for 30 min. In the absence of cytosol, there was little [
14 C]TAG or [ 3 H]apoB d.p.m. associated with the cis-Golgi ( Figure 7A) . Similarly, when VTVs were incubated with Golgi However, these results do not discriminate between VTV bound but not fused with the cis-Golgi and VTV that fused with the Golgi enabling delivery of its VLDL cargo to the cis-Golgi lumen. To address this issue, I took advantage of the observations that apoB100 becomes EndoH-resistant in the cis-Golgi lumen [14] , whereas apoB100 in VTV is EndoH-sensitive ( Figure 7B ). To differentiate between VTV-Golgi association and fusion, VTVs, containing [ 3 H]apoB100, were incubated with cis-Golgi in the presence of cytosol and an ATP-regenerating system at 37
• C. ApoB100 was immunoprecipitated from the isolated cisGolgi, treated with EndoH, separated by SDS/PAGE and autoradiographed. Treated apoB100 isolated from VTV showed that the apoB100 had a reduced molecular mass, suggesting carbohydrate removal as a consequence of the EndoH treatment ( Figure 7B ). By contrast, when apoB100 was isolated from the cis-Golgi post-incubation, EndoH treatment had no effect on the molecular mass of apoB100 ( Figure 7B ), indicating that the apoB100 had been transformed by Golgi enzymes to an EndoHresistant form. These results suggest that VTVs can fuse with hepatic cis-Golgi and can deliver their cargo VLDL to the Golgi lumen.
VTV transports nascent VLDL in a vectorial manner
I sought to determine whether VTV-mediated transport of newly synthesized VLDL to the cis-Golgi is vectorial in nature. I incubated VTV containing [
14 C]TAG with non-radiolabelled hepatic ER at 37
• C in the presence of hepatic cytosol and an ATP-regenerating system for 30 min. Post-incubation, the ER was separated using a sucrose step gradient (see the Experimental section), TAG 
DISCUSSION
The assembly of VLDL starts in the ER, and a two-step model for VLDL formation has been widely accepted [1, 2] . VLDL assembly begins with the translation and translocation of apoB100 across the rough ER membrane [3] . Initially, apoB100 gets partially lipidated in a process that is facilitated by MTP, which contains an apoB-binding domain and a lipid transfer domain [4, 5] . In the second step, TAG is added to the poorly lipidated primordial apoB100-containing particle in the smooth ER [1, 2] . The intracellular site of mature VLDL formation, however, remains a subject of debate. A number of studies based on morphological, immunocytochemical and biochemical experiments support the conclusion that VLDL maturation occurs in the ER [2, [6] [7] [8] [9] [10] [11] , whereas other studies suggest that the Golgi is the site where the formation of mature VLDL takes place [12-14a] . All studies agree, however, that VLDL-apoB100 is transported to the Golgi where it undergoes glycosylation making it EndoH-resistant as well as being phosphorylated [14, 38] .
The present study describes an in vitro system for investigating the formation of VLDL transport vesicles from ER membranes isolated from primary rat hepatocytes. Several lines of evidence indicate that I was successfully able to develop an in vitro budding assay to generate VTVs from the hepatic ER and that the VTVs generated met the criteria of budded vesicles: (i) EM studies show intact vesicles of ∼ 100-120 nm diameter which can accommodate VLDL-sized particles (∼ 80 nm) [2] ; (ii) no VTV formation occurred when the budding assay was performed at 4
• C; (iii) the generation of VTV required cytosol and ATP; (iv) VTVs were sealed, as proteinase K treatment did not degrade the VLDL marker protein, apoB100; (v) VTVs were able to concentrate the cargo protein, apoB100; (vi) VTVs were able to concentrate the ER-to-Golgi v-SNARE, rSec22b, and exclude the ER-resident protein, calnexin, as well as cargo proteins transported by a different vesicle system, albumin and transferrin; and (vii) VTVs were able to fuse with hepatic cis-Golgi. These characteristics of VTVs meet the morphological, biochemical and functional criteria of an ER-to-Golgi transport vesicle and exclude the possibility that the vesicles were generated artefactually.
As defined by their cargo, there are six different vesicles generated from mammalian ER membranes. The bulk of secretory proteins are established to be transported from the ER to the Golgi in COPII-dependent vesicles that fuse with the cis-Golgi utilizing a well-described SNARE complex [39] . A second set of vesicles, which transport GPI-anchored proteins to the Golgi, has been elucidated [40, 41] . A third set of ER-derived vesicles has been described that transport pre-chylomicrons to the Golgi, PCTV. These vesicles do not require COPII proteins to bud from the ER but do require them to fuse with the Golgi [21] . A fourth, less well-defined group of vesicles, transports procollagen from the ER to the Golgi [42] . The procollagen transport vesicle does not require COPII proteins for ER-budding [43] . A fifth vesicle with a distinctive cargo, apoB100-associated VLDL, appears to be COPII-dependent for budding [22] . A sixth, recently identified ER-derived vesicle, is utilized to transport EDEM1 (ER degradation-enhancing a-mannosidase-like protein 1) from the ER to the Golgi [44] . The generation of these vesicles does not require the classical COPII-dependent pathway. These findings suggest that diverse mechanisms regulate the egress of vesicles from the ER and raise the possibility that distinctive cellular machinery might mediate their fusion with the Golgi complex.
VTVs appear to be distinct from ER-derived vesicles involved in transporting albumin, a major liver secretory protein, to the Golgi. The results described in Figure 2 (D) reveal that VTVs are distributed in the light-density portion of the sucrose gradient, whereas albumin and transferrin were found in the mid-portion of the same gradient. These observations suggest that the liver uses different machinery to export VLDL from the ER to the Golgi, which is consistent with a number of reports [14a,22] . Furthermore, the results of the present study show that VTV is different from PCTV, a small intestinal ER-derived vesicle that is utilized for ER-to-Golgi transport of the TAG-rich chylomicrons [20, 21] , in several ways: VTV generation requires Sar1, whereas PCTV generation does not [20, 21] ; VTVs (∼ 100-120 nm) are smaller than PCTVs (∼ 142-500 nm) [21] ; and VTVs do not contain VAMP7 ( Figure 5B ), a v-SNARE localized to PCTV [26, 31] . These findings suggest that the two TAG-rich lipoproteins, hepatic VLDL and intestinal chylomicrons, utilize different vesicles and attendant mechanisms to be transported from the ER to the Golgi. The concentration of Sar1 in VTV when compared with ER suggested that it might play a role in VTV budding from hepatic ER. The results of the present study show that depletion of Sar1 from cytosol and ER prior to their use in the budding assay stopped VTV generation suggesting a role for Sar1. These results also indicate that VTV budding from the hepatic ER is COPII-dependent, which is consistent with prior observations by Gusarova et al. [22] . The size of the circulating VLDL (∼ 80 nm) particle is larger than COPII-coated PTVs (∼ 55-70 nm), therefore it was predicted [45] that a larger vesicle might be involved in ER-to-Golgi transport of VLDL. In a yeast cellfree system, Shimoni et al. [46] have suggested that Sec24p homologues can change the geometry of the COPII cage allowing the transport of larger cargo proteins. These authors have shown that the packaging of the plasma membrane ATPase Pma1p into larger COPII vesicles (87 nm in diameter) requires a Sec24p homologue, Lst1p, which is responsible for the generation of the larger COPII-coated vesicles [46] . I examined VTVs by EM showing that the size of VTVs ranges from 100 nm to 120 nm, which is appropriate to contain VLDLsized particles. In contrast with my observations, VLDL-containing vesicles budded from ER of McA-RH7777 cells were found to be smaller (∼ 55-70 nm) [22] . There are two possibilities to explain the variation in size of the ER-derived VLDL-carrying vesicles: (i) McA-RH7777 cells express high levels of ERK1/2 that leads to overactivation of the MEK/ERK pathway and leads to poorly lipidated, smaller VLDL particles that can be easily packaged into smaller vesicles; and (ii) VLDL in McA-RH7777 cells get fully lipidated in a post-ER compartment or Golgi [22] . However, studies in McA-RH7777 cells from Yamaguchi et al. [11] show that the ER is the site for VLDL maturation and not the Golgi. The results of the present study show that the ER isolated from hepatocytes treated with higher concentrations of OA, had budded VTVs containing more lipidated VLDL, consistent with previously published results by Yamaguchi et al. [11] . The evidence in the present study supports the hypothesis that VLDL particles are fully lipidated in rat hepatic ER: (i) VTVs have a light buoyant density in a sucrose gradient as compared with PTVs; (ii) treatment of rat hepatocytes with 0.4 mM OA resulted in the generation of relatively lighter VTVs as compared with untreated cells; and (iii) EM results show that VTVs are of an appropriate size (∼ 100-120 nm) consistent with their function of carrying mature VLDL particles (∼ 80 nm).
The results pertaining to proteinase K treatment indicate that apoB100 was protected from proteolytic activity by the surrounding membrane of the vesicle. These observations suggest two conclusions. First, VTVs generated from the hepatic ER of OAtreated (+OA) or untreated (−OA) cells are sealed and their cargo, VLDL, is protected from proteases. Secondly, apoB100 within the VTV does not have a cytosolic fragment and thus is protected from proteases in its entirety.
One of the major functions of secretory vesicles is to mediate the delivery of their specific cargoes to specific destinations. In line with this function, the results of the present study show that VTVs fuse with the cis-Golgi ( Figure 7A ) and deliver their cargo, VLDL, to the Golgi lumen as evidenced by the acquisition of EndoH sensitivity experiments ( Figure 7B ). VTVs do not fuse with hepatic ER suggesting that VTVs are involved in anterograde ER-to-Golgi transport of VLDL and that this vesicle is post-ER but pre-Golgi.
In summary, I have identified and characterized in primary hepatocytes a new ER-derived vesicle, VTV, which transports VLDL from the ER to the Golgi in primary hepatocytes. Although VTV budding from the hepatic ER is COPII-dependent, VTVs are larger than PTVs in order to accommodate their larger cargo, the VLDL, and carry distinct cargo. The distribution of VTVs on sucrose density gradient suggests a TAG-filled vesicle because of their light buoyant density compared with PTVs. Treatment of hepatocytes with a higher concentration of OA resulted in VTVs containing more TAG suggesting that the formation of a more lipidated VLDL occurred in hepatic ER under these conditions. Because of the larger size and distinct properties of VTVs, I suggest that primary hepatocytes utilize a highly specialized mechanism to export VLDL from the ER to the Golgi. Identification of the specific proteins, which are required for effective packaging of VLDL into VTV and proteins regulating the formation of the large COPII-dependent VTV, might provide insight into how the liver controls VLDL assembly and secretion.
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